Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Al-imidazole
2. Cu-imidazole
3. Imidazole Acetate
4. Imidazole Citrate
5. Imidazole Conjugate Monoacid
6. Imidazole Monohydrochloride
7. Imidazole Monophosphonate
8. Imidazole Sodium
9. Imidazolium Chloride
1. 1h-imidazole
2. 288-32-4
3. Glyoxaline
4. Imidazol
5. Iminazole
6. Miazole
7. 1,3-diazole
8. Glyoxalin
9. Imutex
10. 1,3-diaza-2,4-cyclopentadiene
11. Pyrro(b)monazole
12. Usaf Ek-4733
13. Pyrro[b]monazole
14. Formamidine, N,n'-vinylene-
15. Glioksal [polish]
16. Glioksal
17. Imd
18. Methanimidamide, N,n'-1,2-ethenediyl-
19. Ccris 3345
20. Ai3-24703
21. Nsc 60522
22. Brn 0103853
23. 1h-imidazole, Dimer
24. N,n'-vinyleneformamidine
25. Chembl540
26. 7gbn705nh1
27. Dtxsid2029616
28. Chebi:16069
29. N,n'-1,2-ethenediylmethanimidamide
30. Mfcd00005183
31. Nsc-60522
32. Dsstox_cid_9616
33. Dsstox_rid_78788
34. Dsstox_gsid_29616
35. 227760-40-9
36. 1h-imidazol
37. Cas-288-32-4
38. Imidazole (8ci)
39. Nsc51860
40. Imidazole, Puriss. P.a., >=99.5% (gc)
41. Einecs 206-019-2
42. Nsc 51860
43. Unii-7gbn705nh1
44. Immidazole
45. Imidazole-
46. 1-h-imidazole
47. Glyoxaline Solution
48. Imidazole, Reagent
49. {pyrro[b]monazole}
50. 1,4-cyclopentadiene
51. Imidazole, Acs Grade
52. 1h-imidazole (9ci)
53. Imidazole [mi]
54. Imidazole [inci]
55. Imidazole Buffer Solution
56. Formamidine,n'-vinylene-
57. Bmse000096
58. Bmse000790
59. Wln: T5m Cnj
60. Ec 206-019-2
61. Enalapril Impurity I
62. Imidazole [usp-rs]
63. Imidazole [who-dd]
64. Ncistruc1_001975
65. Ncistruc2_000693
66. Imidazole, Lr, >=99%
67. 5-23-04-00191 (beilstein Handbook Reference)
68. Mls001055465
69. Bdbm7882
70. Imidazole-buffered Saline (5x)
71. Imidazole-[2-13c,15n2]
72. Hsdb 8449
73. 1,3-diaza-2,4-cyclopentadiene-
74. Imidazole, Reagentplus(r), 99%
75. Zinc901039
76. Imidazole, For Synthesis, 99.5%
77. Bcp26547
78. Hy-d0837
79. Nsc60522
80. Methanimidamide,n'-1,2-ethenediyl-
81. Tox21_201504
82. Tox21_303345
83. S6006
84. Stk362967
85. Akos000120177
86. Am82000
87. Cs-5135
88. Db03366
89. Imidazole, Bioultra, >=99.5% (gc)
90. Ncgc00090984-01
91. Ncgc00090984-02
92. Ncgc00257344-01
93. Ncgc00259055-01
94. 2,4-diazonia-2,4-cyclopentadiene-1-ide
95. Bp-11451
96. Him
97. Smr000057825
98. 1,3-diaza-2,4-cyclopentadiene;glyoxaline
99. Imidazole, Saj Special Grade, >=99.0%
100. Imidazole, Vetec(tm) Reagent Grade, 98%
101. Db-002018
102. Imidazole, 0.5m Buffer Solution, Ph 6.0
103. Imidazole, 0.5m Buffer Solution, Ph 7.0
104. Imidazole, 0.5m Buffer Solution, Ph 7.5
105. Clotrimazole Impurity D [ep Impurity]
106. Ft-0627179
107. Ft-0670295
108. I0001
109. I0014
110. I0288
111. I0290
112. Imidazole, >=99% (titration), Crystalline
113. Imidazole Zone Refined (number Of Passes:30)
114. Imidazole, Acs Reagent, >=99% (titration)
115. C01589
116. P17516
117. Enalapril Maleate Impurity I [ep Impurity]
118. Imidazole Buffer Solution, Bioultra, 1 M In H2o
119. Q328692
120. J-200340
121. Sildenafil Citrate Impurity E [ep Impurity]
122. Imidazole, For Molecular Biology, >=99% (titration)
123. F2190-0638
124. Z1245636370
125. Imidazole, Bioultra, For Molecular Biology, >=99.5% (gc)
126. Imidazole, European Pharmacopoeia (ep) Reference Standard
127. 4286d518-643c-4c69-bce7-519d073f4992
128. Imidazole, Pharmaceutical Impurity Standard, >=95.0% (hplc)
129. Imidazole, United States Pharmacopeia (usp) Reference Standard
130. Imidazole;1,3-diazole; Glyoxaline; 1,3-diazacyclopenta-2,4-diene
131. Ondansetron Hydrochloride Dihydrate Impurity E [ep Impurity]
132. Ondansetron Hydrochloride Impurity, Imidazole- [usp Impurity]
133. Imidazole, Anhydrous, Free-flowing, Redi-dri(tm), Acs Reagent, >=99%
134. Imidazole, Pharmaceutical Secondary Standard; Certified Reference Material
135. Ondansetron Impurity E, European Pharmacopoeia (ep) Reference Standard
| Molecular Weight | 68.08 g/mol |
|---|---|
| Molecular Formula | C3H4N2 |
| XLogP3 | -0.1 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 1 |
| Rotatable Bond Count | 0 |
| Exact Mass | 68.037448136 g/mol |
| Monoisotopic Mass | 68.037448136 g/mol |
| Topological Polar Surface Area | 28.7 Ų |
| Heavy Atom Count | 5 |
| Formal Charge | 0 |
| Complexity | 28.1 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
Imidazole reached peak plasma levels within 15 to 30 minutes in rats dosed with approximately 17 mg/kg bw and disappeared within 4 hours. Similar results were obtained for imidazole with ITF 182, a novel drug called Selezen that consists of the salt of protonated imidazole and 2-hydroxybenzoate in 1:1 molar quantities, with doses containing up to 66 mg imidazole/kg bw. The pharmacokinetic parameters were determined in human studies with ITF 182 in single (248 mg of imidazole) and multiple dose (3 single doses per day) studies. The pharmacokinetic parameters were comparable between different experiments, i.e. single or multiple dosing, oral or rectal applications, or oral tablet or oral drops did not exert marked influences. The main pharmacokinetic parameters in humans after oral intake may be summarized as follows: maximum plasma levels were reached after approximately 3 hours, elimination half-life was approximately 1.8 to 3 hours. Bioavailability was complete. Protein binding was determined to range between 5 to 15 %. In contrast, no effects were noted in a pilot study after dermal application.
OECD; Screening Information Data Set (SIDS) Inital Assessment Report for SIDS Initial Assessment Meeting (SIAM) 17 Imidazole (CAS 288-32-4) p.11 (August 2005). Available from, as of July 30, 2018: https://www.inchem.org/pages/sids.html
Response of enzymes involved in liver drug metabolism to imidazole treatment was determined in several studies. No increase in total microsomal P450 content was observed after a 4 day i.p. administration of 200 mg/kg bw per day in female Sprague-Dawley rats. Statistically significantly increased activities of 7-ethoxycoumarin-O-deethylase (1.7-fold) and Aminopyrine-N-demethylase (1.26-fold) were noted whereas aniline and p-nitrophenol hydroxylases were insignificantly reduced. New Zealand White rabbits treated with imidazole (200 mg/kg bw, 4 days) showed increased total p450-content in liver (1.24-fold) compared with controls and a 4.47-fold increase of the isozyme 3a. No significant changes were noted in pretreated Syrian Hamsters of both sexes (200 mg/kg bw, 4 days) with respect to relative liver weight, total microsomal p450-content, microsomal and cytosolic enzyme activities involved in phase I (demethylation of p-nitroanisole and ethylmorphine, NADPH-Cytochrome C-reductase) and phase II drug metabolism (sulfotransferase, glutathione transferase).
OECD; Screening Information Data Set (SIDS) Inital Assessment Report for SIDS Initial Assessment Meeting (SIAM) 17 Imidazole (CAS 288-32-4) p.11 (August 2005). Available from, as of July 30, 2018: https://www.inchem.org/pages/sids.html
... Elimination half-life /in humans/ was approximately 1.8 to 3 hours.
OECD; Screening Information Data Set (SIDS) Inital Assessment Report for SIDS Initial Assessment Meeting (SIAM) 17 Imidazole (CAS 288-32-4) p.11 (August 2005). Available from, as of July 30, 2018: https://www.inchem.org/pages/sids.html
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
29
PharmaCompass offers a list of Imidazole API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Imidazole manufacturer or Imidazole supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Imidazole manufacturer or Imidazole supplier.
PharmaCompass also assists you with knowing the Imidazole API Price utilized in the formulation of products. Imidazole API Price is not always fixed or binding as the Imidazole Price is obtained through a variety of data sources. The Imidazole Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A IMD manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of IMD, including repackagers and relabelers. The FDA regulates IMD manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. IMD API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A IMD supplier is an individual or a company that provides IMD active pharmaceutical ingredient (API) or IMD finished formulations upon request. The IMD suppliers may include IMD API manufacturers, exporters, distributors and traders.
click here to find a list of IMD suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A IMD DMF (Drug Master File) is a document detailing the whole manufacturing process of IMD active pharmaceutical ingredient (API) in detail. Different forms of IMD DMFs exist exist since differing nations have different regulations, such as IMD USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A IMD DMF submitted to regulatory agencies in the US is known as a USDMF. IMD USDMF includes data on IMD's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The IMD USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of IMD suppliers with USDMF on PharmaCompass.
IMD Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of IMD GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right IMD GMP manufacturer or IMD GMP API supplier for your needs.
A IMD CoA (Certificate of Analysis) is a formal document that attests to IMD's compliance with IMD specifications and serves as a tool for batch-level quality control.
IMD CoA mostly includes findings from lab analyses of a specific batch. For each IMD CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
IMD may be tested according to a variety of international standards, such as European Pharmacopoeia (IMD EP), IMD JP (Japanese Pharmacopeia) and the US Pharmacopoeia (IMD USP).
